Sabinsa Founder Publishes New Book on Curcuminoids

From left, Shri Deepak Goyal, CEO, Tirupathi Group of companies; Shri Pratap Chandra, Hon. Minister of State for Micro, Small and Medium Enterprises and Animal Husbandry, Government of India; Dr. Muhammed Majeed, Chairman and Managing Director, Sami-Sabinsa Group; Padmashri Dr. D. S. Rana, Chirman, Sir Gangaram Hospital, Delhi; Dr. Pushpa Vijayaraghavan, Director, Sathguru Management Consultants; Dr. Sudhir Kalhan, Chairman, Institute of Minimal Access, Metabolic and Bariatric Surgery, Sir Gangaram Hospital Delhi hold copies of the book Reductive Metabolites of Curcuminoids at its launch at the 5th ASSOCHAM National Symposium on Nutraceuticals, in New Delhi, India. Image courtesy of Sabinsa.

East Windsor, NJ—Sabinsa’s Founder, Chairman, and Managing Director Dr. Muhammed Majeed announced the publication of a new book, titled Reductive Metabolites of Curcuminoids in a press release.

Authored by Dr. Majeed and N. Kalyanam, Ph.D., President of R&D at Sabinsa, as well as other members of the Sami-Sabinsa Group’s technical staff, the book walks through the transformation of curcumin into its metabolites inside the body, and discusses the significance of major metabolites. The book also reviews the scientific evidence on the effects of microbiota on what has been called “poor bioavailability,” and discusses the unmistakable role of microbiota in transforming curcumin into its major pharmacologically potent reductive metabolite, tetrahydrocurcumin.

Related: Company Profile: Sabinsa
Sabinsa’s C3 Reduct Self-Affirmed GRAS
Study: Curcumin, BioPerine Potentially Beneficial for Mesothelioma Patients

Dr. Majeed said in the release: “The central theme of the book is to emphasize that the effects of curcumin observed in animal models and in human trials are the aggregate benefits of curcumin and the reductive metabolites of curcuminoids.”

The Sabinsa staff will have copies of the book at booth #4131 at SupplySide West in Las Vegas, NV, October 17-18.